Business Insider4d
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a ...
TMCnet23d
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
(Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), ...
Yahoo Finance3d
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
Zone 1, Moderated Digital Poster 1, Nov 17, 2024, 03:35 PM – 3:40 PM. In addition, the following two abstracts on ...
The Bakersfield Californian14d
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three ...
Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been ...
Mena FN23d
Tectonic Therapeutic To Present Phase 1A Data At AHA 2024
(MENAFN- GlobeNewsWire - Nasdaq) American Heart Association (AHA) poster to be presented on November 16, 2024 WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ ...